Atenolol View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-09

AUTHORS

Alison N. Wadworth, David Murdoch, Rex N. Brogden

ABSTRACT

SynopsisAtenolol is a selective β1-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic use of the drug has been expanded and become better defined since it was first reviewed in the Journal in 1979.Atenolol is effective and generally well tolerated in patients with all grades of hypertension. Data from comparative studies show that when administered orally, atenolol reduces blood pressure to a similar extent, and in a similar proportion of patients, as usual therapeutic doses of other β- adrenoceptor antagonists (such as acebutolol, celiprolol, betaxolol, indenolol, metoprolol, nadolol, pindolol, propranolol, tertatolol), angiotensin converting enzyme (ACE) inhibitors (e.g. captopril, enalapril and lisinopril), calcium antagonists (e.g. amlodipine, diltiazem, felodipine, isradipine, nitrendipine, nifedipine, verapamil), doxazosin, ketanserin and α-methyldopa. Atenolol effectively lowers blood pressure in elderly patients with hypertension and in women with hypertension associated with pregnancy, and improves objective and subjective indices in patients with stable angina pectoris. Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. Early intervention with intravenous atenolol followed by oral maintenance therapy reduces infarct recurrence and cardiovascular mortality in patients with known or suspected myocardial infarction. There is also encouraging evidence of reduced mortality from cardiovascular disease during long term therapy with atenolol in patients with hypertension.Atenolol is well tolerated in most patients. Increases in plasma levels of both total triglycerides and very low density lipoprotein (VLDL) triglycerides have accompanied atenolol therapy although the clinical relevance, if any, of longer term metabolic effects has yet to be determined. Its low lipid solubility and limited brain penetration results in a lower incidence of central nervous system effects than that associated with propranolol.After many years of clinical usage atenolol is a well established treatment option in several areas of cardiovascular medicine such as mild to moderate hypertension and stable angina pectoris. Furthermore, it has also shown potential in the treatment of some cardiac arrhythmias and has been associated with reduced cardiovascular mortality in patients with hypertension and in patients with myocardial infarction.Pharmacodynamic PropertiesAtenolol is a selective and long acting β1-adrenoceptor antagonist. In patients with hypertension, oral administration of atenolol significantly reduces resting systolic and diastolic blood pressures and attenuates the blood pressure increase induced by exercise. In some studies, long term administration of atenolol 50 to 100mg daily improved left ventricular hypertrophy when present before treatment. In patients with coronary artery disease the antihypertensive effects of atenolol are accompanied by reductions in heart rate (8 to 34%) and rate-pressure product (9 to 40%). Atenolol improves indices of oxygen consumption in patients with acute myocardial infarction. Short or long term administration of atenolol 50 to 100mg daily reduces blood pressure in pregnant women.Although impaired glucose tolerance and increased insulin resistance have been reported in some patients treated with atenolol, improved glucose tolerance has been reported in others. Increases in plasma total triglycerides and very low density lipoprotein triglycerides, and decreases in high density lipoprotein cholesterol generally occur after several months’ treatment with atenolol, but these changes are less pronounced than those associated with propranolol and a trend towards a reduction in effect has been noted during long term administration.Atenolol 50 to 125mg impairs respiratory function in asthmatic patients, following single or multiple doses, to a lesser extent than propranolol, and does not significantly decrease the bronchodilatation effect of inhaled salbutamol during short or long term treatment.Pharmacokinetic PropertiesFollowing oral administration, about 50 to 60% of an atenolol dose is absorbed with maximum plasma concentrations reached within 2 to 4 hours. Atenolol is widely distributed in the body (although only a small proportion of an administered dose reaches the brain), and readily crosses the placenta. In adult patients with normal renal function the elimination half-life is about 5 to 7 hours and total clearance is about 6 L/h (100 ml/min) per 1.73m2. A shorter elimination half-life (4.5 hours) has been observed in children. However, there are wide intra- and interindividual differences in the pharmacokinetic properties of atenolol. Most absorbed atenolol is excreted unchanged in the urine. Accumulation into breast milk has been reported but plasma concentrations are negligible in infants. In patients with renal dysfunction the elimination rate is decreased and is related to glomerular filtration rate.Therapeutic EfficacyDuring long term follow-up trials with atenolol, generally 50 to 100mg once daily alone or in combination with a diuretic, goal blood pressures are achieved in about two-thirds of all patients with mild to moderate hypertension. The greatest reductions in blood pressure occur in the first 2 weeks of treatment, and blood pressure remains within normal limits during extended therapy without major adjustment of dosage.Atenolol 50 to lOOmg daily is clearly more effective than placebo in reducing blood pressure, and in comparative trials it reduced blood pressure in a similar proportion of patients, and to a similar extent, as usual therapeutic doses of other β-adrenoceptor antagonists (acebutolol, celiprolol, betaxolol, indenolol, SR metoprolol, nadolol, SR pindolol, SR propranolol, tertatolol), ACE inhibitors [captopril (100mg), enalapril (20 to 40mg) and lisinopril (20 to 80mg)], calcium antagonists [amlodipine (2.5 to 10mg), diltiazem (240 to 360mg), felodipine (10 to 20mg), isradipine (5 to 20mg), SR nifedipine (20 to 40mg), SR verapamil (240mg) and nitrendipine (20 to 40mg)], doxazosin 1 to 16mg, ketanserin 40 to 80mg and α-methyldopa 1500mg daily. Elderly patients and women with hypertension associated with pregnancy respond well to treatment with atenolol 50 and 50 to 200mg daily, respectively.In patients with stable angina pectoris, oral atenolol 100mg daily was superior to placebo and at least as effective as usual therapeutic doses of other antianginal agents in reducing the severity and frequency of anginal attacks, reducing glyceryl trinitrate consumption, improving exercise duration, and extending time to lmm ST-segment depression. Atenolol appears to eliminate the morning ischaemic episode peak in patients with silent ischaemia.In patients with hypertension, with or without evidence of ischaemia, long term atenolol therapy reduced the mortality from myocardial infarction or stroke. In addition, early initiation of atenolol therapy reduced the incidence of both vascular mortality and the occurrence of non-fatal cardiac arrests and reinfarction in patients with suspected myocardial infarction.Preliminary investigation in patients with paroxysmal supraventricular tachycardia revealed that atenolol reduced the occurrence of supraventricular tachycardia in up to 70% of patients. This benefit was maintained during long term follow-up and atenolol improved the clinical course of patients with sustained paroxysmal reciprocating supraventricular tachycardia. Following coronary artery surgery, orally administered atenolol was significantly superior to placebo in reducing the incidence of supraventricular arrhythmias and atrial fibrillation. Control of ventricular arrhythmias has also been achieved using oral atenolol therapy.TolerabilityThe most frequently reported adverse effects experienced during oral atenolol therapy for hypertension, angina pectoris and arrhythmias are bradycardia (0.6 to 10%), cold extremities/ Raynaud’s phenomenon (2 to 35%), gastrointestinal symptoms (0.5 to 32%), fatigue/weakness (1 to 51%), nightmares/sleep disturbances (6 to 26%), headache (1 to 18%), and sexual disturbances (1 to 14%). In general these effects were mild, occurred more frequently during baseline phases, usually become less frequent with continued therapy and, in most studies, necessitated withdrawal of treatment from only 3 to 6% of patients. Data from comparative studies suggest that the tolerability profile of atenolol is similar to that of other antihypertensive agents although the pattern of effects differed between drug classes. Both hypotension and bradycardia have been observed after intravenous administration of atenolol in patients with myocardial infarction. Atenolol therapy has not been associated with ophthalmological changes or clinically significant changes in haematological or biochemical indices.Dosage and AdministrationMost patients with hypertension respond to once daily oral administration of atenolol 50 to 100mg. The full effect is usually established within 2 weeks. If an optimal response is not achieved an additional antihypertensive agent such as a diuretic, calcium antagonist or ACE inhibitor could be added. It is unlikely that increasing the atenolol dose above 100 mg/day will result in additional benefit for patients receiving monotherapy or combination therapy. The majority of patients with angina pectoris will respond to 100mg daily given orally. For patients with arrhythmias a suitable initial dose is 2.5 to 5mg injected intravenously (1mg/min). This may be repeated at 5-minute intervals until a response is observed, up to a maximum dosage of 10mg. If atenolol is administered by infusion the initial dose should be 0.15 mg/kg over 20 minutes. If required, the injection or infusion may be repeated every 12 hours. Once arrhythmias have been controlled a suitable maintenance dose is 50 to 100mg once daily.For patients with suspected myocardial infarction, presenting within 12 hours of the onset of chest pain, intravenous atenolol (5mg infused over 5 minutes) should be administered immediately. A second 5mg dose may be given 10 minutes later. 15 minutes after the final infusion an oral 50mg dose should be administered. A second oral 50mg dose should be given after 12 hours and after a further 12 hours maintenance treatment with 100mg once daily should be initiated.Dosage adjustment is required in patients with severe renal impairment (creatinine clearance < 35 ml/min/ 1.73m2). Patients undergoing dialysis should be given an oral 50mg dose after each dialysis. Atenolol is not recommended for children, patients with overt heart failure or as first therapy in patients with asthma. Atenolol should be administered with caution in patients receiving concomitant class I antiarrhythmic agents or verapamil as these drugs have similar electrophysiological effects. Care must also be taken when administering atenolol to patients whose cardiac reserve is poor. More... »

PAGES

468-510

References to SciGraph publications

  • 1983-06. The Effect of Long Term Therapy for Essential Hypertension with Atenolol and Chlorthalidone on Carbohydrate Tolerance in DRUGS
  • 1985-01. A comparison of the effects of atenolol and metoprolol on attention in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1991-01. The effect of celiprolol on the blood lipid profile in hypertensive patients with high cholesterol levels in CARDIOVASCULAR DRUGS AND THERAPY
  • 1983-06. Atenolol and Left Ventricular Hypertrophy in DRUGS
  • 1988-09. Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1988-04. Short‐term behavioral effects of beta‐adrenergic medications in men with mild hypertension in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1985-01. Atenolol versus pindolol: Side-effects in hypertension in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1982-09. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1984-01. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1989-05. Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-06. β-Blockers in Asthma in DRUGS
  • 1983-06. Effect of β-Blockade on the Pressor Response to Coffee plus Smoking in Patients with Mild Hypertension in DRUGS
  • 1983-06. Atenolol and Liver Function in DRUGS
  • 1983-06. Pharmacokinetics of Atenolol in Pregnancy and Lactation in DRUGS
  • 1983-06. Effects of Short and Long Term β-Blockade on Changes in Blood Pressure Caused by Cigarette Smoking in Normotensive and Hypertensive Subjects in DRUGS
  • 1983-06. Atenolol in the Management of Hypertension during Pregnancy in DRUGS
  • 1983-06. Atenolol in the Treatment of Hypertension of Pregnancy in DRUGS
  • 1983-06. Transplacental Passage and Breast Milk Accumulation of Atenolol in Humans in DRUGS
  • 1988-04. β-Blockers and Calcium Antagonists in Angina Pectoris in DRUGS
  • 1983-06. Short Term Evaluation of Atenolol in Hospitalised Patients with Chronic Ventricular Arrhythmias in DRUGS
  • 1983-06. Treatment with Atenolol of Hypertension in Pregnancy in DRUGS
  • 1985-01. Effect of atenolol on car drivers in a prolonged stress situation in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-06. Atenolol Dose-Finding Studies in DRUGS
  • 1987-07. Airway response to salbutamol and to ipratropium bromide after non-selective and cardioselective beta-blocker in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1992-06. Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans in CARDIOVASCULAR DRUGS AND THERAPY
  • 1983-06. Indonesian Multicentre Trial in Hypertension in DRUGS
  • 1991-05. The effects of chronic dosing on the β1 and β2-adrenoceptor antagonism of betaxolol and atenolol in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-06. Effect of Liver Function on β-Blocker Kinetics in DRUGS
  • 1983-06. Cardioselectivity and Partial Agonist Activity in the Antianginal Efficacy of the β-Adrenoceptor Antagonists in DRUGS
  • 1983-06. Atenolol in Unstable Angina in DRUGS
  • 1983-06. Hypertensive Patients Treated with Atenolol in DRUGS
  • 1988-07. Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1985-05. Comparison of atenolol 50 mg and 100 mg as initial treatment in uncomplicated mild to moderate hypertension in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1990-01. Comparison of bopindolol and atenolol in chronic stable angina pectoris in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-06. Atenolol and Ventricular Ectopic Beats in DRUGS
  • 1983-06. Atenolol in Orally Treated Diabetic Patients in DRUGS
  • 1984-09. Effect of adrenaline on myocardial oxygen consumption during selective and non-selective beta-adrenoceptor blockade comparison of atenolol and pindolol in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1984-09. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-06. β-Adrenoceptor-linked Na/K ATPase in DRUGS
  • 1983-06. Antihypertensive Effects and Kidney Function in Hypertensive Patients Treated with Atenolol and Oxprenolol in DRUGS
  • 1991-04. The circadian heart rate but not blood pressure profile is influenced by the timing of β-blocker administration in hypertensives in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1988-08. Multicentre Study of the Efficacy and Tolerance of Acebutolol versus Atenolol in the Long Term Treatment of Mild Arterial Hypertension in DRUGS
  • 1983-06. 9 Years’ Experience with Atenolol in the Treatment of Hypertension in DRUGS
  • 1987-01. Atenolol for ventricular ectopy: A dose‐response study in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1985-05. Acute effect of indenolol on human airways in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1990-07. Nocturnal oscillations in plasma renin activity during sleep in hypertensive patients: the influence of perindopril in JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • 1985-11-09. Effects of betaxolol, propranolol, and atenolol on isoproterenol‐induced beta‐adrenoceptor responses in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1989-12-04. Pharmacokinetics and pharmacodynamics of atenolol in children in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1990-02. Evolution of atenolol kinetics when hypothyroidism is corrected in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1983-03. Atenolol interaction with aspirin, allopurinol, and ampicillin in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1990-08. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease in CARDIOVASCULAR DRUGS AND THERAPY
  • 1983-06. Atenolol in Angina in DRUGS
  • 1979-06. Atenolol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Angina Pectoris and Hypertension in DRUGS
  • 1985-03. Treatment of essential hypertension: Changes in blood pressure echocardiography and electrocardiography on three therapeutic regimes in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 1990-03. Atenolol in dilated cardiomyopathy: A clinical instrumental study in CARDIOVASCULAR DRUGS AND THERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003495-199142030-00007

    DOI

    http://dx.doi.org/10.2165/00003495-199142030-00007

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1021698570

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/1720383


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1116", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Physiology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Arrhythmias, Cardiac", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Atenolol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Coronary Disease", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Evaluation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypertension", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand", 
              "id": "http://www.grid.ac/institutes/grid.420067.7", 
              "name": [
                "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wadworth", 
            "givenName": "Alison N.", 
            "id": "sg:person.01065012230.06", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065012230.06"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand", 
              "id": "http://www.grid.ac/institutes/grid.420067.7", 
              "name": [
                "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Murdoch", 
            "givenName": "David", 
            "id": "sg:person.01026511116.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026511116.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand", 
              "id": "http://www.grid.ac/institutes/grid.420067.7", 
              "name": [
                "Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Brogden", 
            "givenName": "Rex N.", 
            "id": "sg:person.01232517615.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232517615.24"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf00314809", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052228201", 
              "https://doi.org/10.1007/bf00314809"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1988.54", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027933705", 
              "https://doi.org/10.1038/clpt.1988.54"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00315224", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023933809", 
              "https://doi.org/10.1007/bf00315224"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf03348625", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041545801", 
              "https://doi.org/10.1007/bf03348625"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00013", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023531610", 
              "https://doi.org/10.2165/00003495-198300252-00013"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1983.34", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035061855", 
              "https://doi.org/10.1038/clpt.1983.34"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00543336", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012113650", 
              "https://doi.org/10.1007/bf00543336"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00051147", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008110367", 
              "https://doi.org/10.1007/bf00051147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00064", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041104400", 
              "https://doi.org/10.2165/00003495-198300252-00064"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00015", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050590745", 
              "https://doi.org/10.2165/00003495-198300252-00015"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00061", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042067518", 
              "https://doi.org/10.2165/00003495-198300252-00061"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00543719", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024722144", 
              "https://doi.org/10.1007/bf00543719"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00021", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024610242", 
              "https://doi.org/10.2165/00003495-198300252-00021"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198800354-00011", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006554903", 
              "https://doi.org/10.2165/00003495-198800354-00011"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-197917060-00001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007024415", 
              "https://doi.org/10.2165/00003495-197917060-00001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00063", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028142717", 
              "https://doi.org/10.2165/00003495-198300252-00063"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00114235", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052316887", 
              "https://doi.org/10.1007/bf00114235"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00058", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048647516", 
              "https://doi.org/10.2165/00003495-198300252-00058"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00546701", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026163841", 
              "https://doi.org/10.1007/bf00546701"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00556887", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043627001", 
              "https://doi.org/10.1007/bf00556887"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00050", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028087420", 
              "https://doi.org/10.2165/00003495-198300252-00050"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00679788", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012896847", 
              "https://doi.org/10.1007/bf00679788"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039300203", 
              "https://doi.org/10.2165/00003495-198300252-00009"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00075", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027864937", 
              "https://doi.org/10.2165/00003495-198300252-00075"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00017", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031521587", 
              "https://doi.org/10.2165/00003495-198300252-00017"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00265982", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026394691", 
              "https://doi.org/10.1007/bf00265982"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00051", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036487532", 
              "https://doi.org/10.2165/00003495-198300252-00051"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1989.198", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038050110", 
              "https://doi.org/10.1038/clpt.1989.198"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00040", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024510787", 
              "https://doi.org/10.2165/00003495-198300252-00040"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1985.223", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036603739", 
              "https://doi.org/10.1038/clpt.1985.223"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00543720", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017575493", 
              "https://doi.org/10.1007/bf00543720"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00060", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041628380", 
              "https://doi.org/10.2165/00003495-198300252-00060"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00609677", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022238970", 
              "https://doi.org/10.1007/bf00609677"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00561365", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030807023", 
              "https://doi.org/10.1007/bf00561365"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00265862", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016200197", 
              "https://doi.org/10.1007/bf00265862"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02395202", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040426368", 
              "https://doi.org/10.1007/bf02395202"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198800362-00009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005571736", 
              "https://doi.org/10.2165/00003495-198800362-00009"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00053", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004932076", 
              "https://doi.org/10.2165/00003495-198300252-00053"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01857761", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005603429", 
              "https://doi.org/10.1007/bf01857761"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01856511", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011645853", 
              "https://doi.org/10.1007/bf01856511"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00544082", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045490019", 
              "https://doi.org/10.1007/bf00544082"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00026", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014777390", 
              "https://doi.org/10.2165/00003495-198300252-00026"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00074", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035816881", 
              "https://doi.org/10.2165/00003495-198300252-00074"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00558246", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003035238", 
              "https://doi.org/10.1007/bf00558246"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00542322", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049097189", 
              "https://doi.org/10.1007/bf00542322"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00042", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023486384", 
              "https://doi.org/10.2165/00003495-198300252-00042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00055", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009622562", 
              "https://doi.org/10.2165/00003495-198300252-00055"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00067", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007269274", 
              "https://doi.org/10.2165/00003495-198300252-00067"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00044", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006145850", 
              "https://doi.org/10.2165/00003495-198300252-00044"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00543966", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033763100", 
              "https://doi.org/10.1007/bf00543966"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00062", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046387025", 
              "https://doi.org/10.2165/00003495-198300252-00062"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.1987.20", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038511633", 
              "https://doi.org/10.1038/clpt.1987.20"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00035", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049915737", 
              "https://doi.org/10.2165/00003495-198300252-00035"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-198300252-00018", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047102313", 
              "https://doi.org/10.2165/00003495-198300252-00018"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00543717", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003850908", 
              "https://doi.org/10.1007/bf00543717"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1991-09", 
        "datePublishedReg": "1991-09-01", 
        "description": "SynopsisAtenolol is a selective \u03b21-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic use of the drug has been expanded and become better defined since it was first reviewed in the Journal in 1979.Atenolol is effective and generally well tolerated in patients with all grades of hypertension. Data from comparative studies show that when administered orally, atenolol reduces blood pressure to a similar extent, and in a similar proportion of patients, as usual therapeutic doses of other \u03b2- adrenoceptor antagonists (such as acebutolol, celiprolol, betaxolol, indenolol, metoprolol, nadolol, pindolol, propranolol, tertatolol), angiotensin converting enzyme (ACE) inhibitors (e.g. captopril, enalapril and lisinopril), calcium antagonists (e.g. amlodipine, diltiazem, felodipine, isradipine, nitrendipine, nifedipine, verapamil), doxazosin, ketanserin and \u03b1-methyldopa. Atenolol effectively lowers blood pressure in elderly patients with hypertension and in women with hypertension associated with pregnancy, and improves objective and subjective indices in patients with stable angina pectoris. Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. Early intervention with intravenous atenolol followed by oral maintenance therapy reduces infarct recurrence and cardiovascular mortality in patients with known or suspected myocardial infarction. There is also encouraging evidence of reduced mortality from cardiovascular disease during long term therapy with atenolol in patients with hypertension.Atenolol is well tolerated in most patients. Increases in plasma levels of both total triglycerides and very low density lipoprotein (VLDL) triglycerides have accompanied atenolol therapy although the clinical relevance, if any, of longer term metabolic effects has yet to be determined. Its low lipid solubility and limited brain penetration results in a lower incidence of central nervous system effects than that associated with propranolol.After many years of clinical usage atenolol is a well established treatment option in several areas of cardiovascular medicine such as mild to moderate hypertension and stable angina pectoris. Furthermore, it has also shown potential in the treatment of some cardiac arrhythmias and has been associated with reduced cardiovascular mortality in patients with hypertension and in patients with myocardial infarction.Pharmacodynamic PropertiesAtenolol is a selective and long acting \u03b21-adrenoceptor antagonist. In patients with hypertension, oral administration of atenolol significantly reduces resting systolic and diastolic blood pressures and attenuates the blood pressure increase induced by exercise. In some studies, long term administration of atenolol 50 to 100mg daily improved left ventricular hypertrophy when present before treatment. In patients with coronary artery disease the antihypertensive effects of atenolol are accompanied by reductions in heart rate (8 to 34%) and rate-pressure product (9 to 40%). Atenolol improves indices of oxygen consumption in patients with acute myocardial infarction. Short or long term administration of atenolol 50 to 100mg daily reduces blood pressure in pregnant women.Although impaired glucose tolerance and increased insulin resistance have been reported in some patients treated with atenolol, improved glucose tolerance has been reported in others. Increases in plasma total triglycerides and very low density lipoprotein triglycerides, and decreases in high density lipoprotein cholesterol generally occur after several months\u2019 treatment with atenolol, but these changes are less pronounced than those associated with propranolol and a trend towards a reduction in effect has been noted during long term administration.Atenolol 50 to 125mg impairs respiratory function in asthmatic patients, following single or multiple doses, to a lesser extent than propranolol, and does not significantly decrease the bronchodilatation effect of inhaled salbutamol during short or long term treatment.Pharmacokinetic PropertiesFollowing oral administration, about 50 to 60% of an atenolol dose is absorbed with maximum plasma concentrations reached within 2 to 4 hours. Atenolol is widely distributed in the body (although only a small proportion of an administered dose reaches the brain), and readily crosses the placenta. In adult patients with normal renal function the elimination half-life is about 5 to 7 hours and total clearance is about 6 L/h (100 ml/min) per 1.73m2. A shorter elimination half-life (4.5 hours) has been observed in children. However, there are wide intra- and interindividual differences in the pharmacokinetic properties of atenolol. Most absorbed atenolol is excreted unchanged in the urine. Accumulation into breast milk has been reported but plasma concentrations are negligible in infants. In patients with renal dysfunction the elimination rate is decreased and is related to glomerular filtration rate.Therapeutic EfficacyDuring long term follow-up trials with atenolol, generally 50 to 100mg once daily alone or in combination with a diuretic, goal blood pressures are achieved in about two-thirds of all patients with mild to moderate hypertension. The greatest reductions in blood pressure occur in the first 2 weeks of treatment, and blood pressure remains within normal limits during extended therapy without major adjustment of dosage.Atenolol 50 to lOOmg daily is clearly more effective than placebo in reducing blood pressure, and in comparative trials it reduced blood pressure in a similar proportion of patients, and to a similar extent, as usual therapeutic doses of other \u03b2-adrenoceptor antagonists (acebutolol, celiprolol, betaxolol, indenolol, SR metoprolol, nadolol, SR pindolol, SR propranolol, tertatolol), ACE inhibitors [captopril (100mg), enalapril (20 to 40mg) and lisinopril (20 to 80mg)], calcium antagonists [amlodipine (2.5 to 10mg), diltiazem (240 to 360mg), felodipine (10 to 20mg), isradipine (5 to 20mg), SR nifedipine (20 to 40mg), SR verapamil (240mg) and nitrendipine (20 to 40mg)], doxazosin 1 to 16mg, ketanserin 40 to 80mg and \u03b1-methyldopa 1500mg daily. Elderly patients and women with hypertension associated with pregnancy respond well to treatment with atenolol 50 and 50 to 200mg daily, respectively.In patients with stable angina pectoris, oral atenolol 100mg daily was superior to placebo and at least as effective as usual therapeutic doses of other antianginal agents in reducing the severity and frequency of anginal attacks, reducing glyceryl trinitrate consumption, improving exercise duration, and extending time to lmm ST-segment depression. Atenolol appears to eliminate the morning ischaemic episode peak in patients with silent ischaemia.In patients with hypertension, with or without evidence of ischaemia, long term atenolol therapy reduced the mortality from myocardial infarction or stroke. In addition, early initiation of atenolol therapy reduced the incidence of both vascular mortality and the occurrence of non-fatal cardiac arrests and reinfarction in patients with suspected myocardial infarction.Preliminary investigation in patients with paroxysmal supraventricular tachycardia revealed that atenolol reduced the occurrence of supraventricular tachycardia in up to 70% of patients. This benefit was maintained during long term follow-up and atenolol improved the clinical course of patients with sustained paroxysmal reciprocating supraventricular tachycardia. Following coronary artery surgery, orally administered atenolol was significantly superior to placebo in reducing the incidence of supraventricular arrhythmias and atrial fibrillation. Control of ventricular arrhythmias has also been achieved using oral atenolol therapy.TolerabilityThe most frequently reported adverse effects experienced during oral atenolol therapy for hypertension, angina pectoris and arrhythmias are bradycardia (0.6 to 10%), cold extremities/ Raynaud\u2019s phenomenon (2 to 35%), gastrointestinal symptoms (0.5 to 32%), fatigue/weakness (1 to 51%), nightmares/sleep disturbances (6 to 26%), headache (1 to 18%), and sexual disturbances (1 to 14%). In general these effects were mild, occurred more frequently during baseline phases, usually become less frequent with continued therapy and, in most studies, necessitated withdrawal of treatment from only 3 to 6% of patients. Data from comparative studies suggest that the tolerability profile of atenolol is similar to that of other antihypertensive agents although the pattern of effects differed between drug classes. Both hypotension and bradycardia have been observed after intravenous administration of atenolol in patients with myocardial infarction. Atenolol therapy has not been associated with ophthalmological changes or clinically significant changes in haematological or biochemical indices.Dosage and AdministrationMost patients with hypertension respond to once daily oral administration of atenolol 50 to 100mg. The full effect is usually established within 2 weeks. If an optimal response is not achieved an additional antihypertensive agent such as a diuretic, calcium antagonist or ACE inhibitor could be added. It is unlikely that increasing the atenolol dose above 100 mg/day will result in additional benefit for patients receiving monotherapy or combination therapy. The majority of patients with angina pectoris will respond to 100mg daily given orally. For patients with arrhythmias a suitable initial dose is 2.5 to 5mg injected intravenously (1mg/min). This may be repeated at 5-minute intervals until a response is observed, up to a maximum dosage of 10mg. If atenolol is administered by infusion the initial dose should be 0.15 mg/kg over 20 minutes. If required, the injection or infusion may be repeated every 12 hours. Once arrhythmias have been controlled a suitable maintenance dose is 50 to 100mg once daily.For patients with suspected myocardial infarction, presenting within 12 hours of the onset of chest pain, intravenous atenolol (5mg infused over 5 minutes) should be administered immediately. A second 5mg dose may be given 10 minutes later. 15 minutes after the final infusion an oral 50mg dose should be administered. A second oral 50mg dose should be given after 12 hours and after a further 12 hours maintenance treatment with 100mg once daily should be initiated.Dosage adjustment is required in patients with severe renal impairment (creatinine clearance < 35 ml/min/ 1.73m2). Patients undergoing dialysis should be given an oral 50mg dose after each dialysis. Atenolol is not recommended for children, patients with overt heart failure or as first therapy in patients with asthma. Atenolol should be administered with caution in patients receiving concomitant class I antiarrhythmic agents or verapamil as these drugs have similar electrophysiological effects. Care must also be taken when administering atenolol to patients whose cardiac reserve is poor.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003495-199142030-00007", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1084788", 
            "issn": [
              "0012-6667", 
              "1179-1950"
            ], 
            "name": "Drugs", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "42"
          }
        ], 
        "keywords": [
          "stable angina pectoris", 
          "usual therapeutic doses", 
          "long-term administration", 
          "low density lipoprotein triglycerides", 
          "oral atenolol therapy", 
          "atenolol 50", 
          "blood pressure", 
          "atenolol therapy", 
          "angina pectoris", 
          "\u03b21-adrenoceptor antagonist", 
          "myocardial infarction", 
          "\u03b2-adrenoceptor antagonists", 
          "density lipoprotein triglycerides", 
          "calcium antagonists", 
          "term administration", 
          "supraventricular tachycardia", 
          "therapeutic doses", 
          "oral administration", 
          "oral atenolol", 
          "intravenous atenolol", 
          "elderly patients", 
          "cardiovascular mortality", 
          "glucose tolerance", 
          "ACE inhibitors", 
          "antihypertensive agents", 
          "supraventricular arrhythmias", 
          "lipoprotein triglycerides", 
          "initial dose", 
          "total triglycerides", 
          "plasma concentrations", 
          "intravenous administration", 
          "Pharmacokinetic PropertiesFollowing oral administration", 
          "high-density lipoprotein cholesterol", 
          "class I antiarrhythmic agents", 
          "angiotensin converting enzyme (ACE) inhibitors", 
          "long-term metabolic effects", 
          "central nervous system effects", 
          "non-fatal cardiac arrest", 
          "selective \u03b21-adrenoceptor antagonist", 
          "grades of hypertension", 
          "oral maintenance therapy", 
          "impair respiratory function", 
          "glyceryl trinitrate consumption", 
          "evidence of ischaemia", 
          "additional antihypertensive agents", 
          "suitable initial dose", 
          "goal blood pressure", 
          "severe renal impairment", 
          "overt heart failure", 
          "reduced cardiovascular mortality", 
          "blood pressure increase", 
          "impaired glucose tolerance", 
          "normal renal function", 
          "ST-segment depression", 
          "coronary artery surgery", 
          "diastolic blood pressure", 
          "rate-pressure product", 
          "plasma total triglycerides", 
          "density lipoprotein cholesterol", 
          "glomerular filtration rate", 
          "daily oral administration", 
          "majority of patients", 
          "long-term therapy", 
          "coronary artery disease", 
          "long-term follow", 
          "weeks of treatment", 
          "fatigue/weakness", 
          "nervous system effects", 
          "left ventricular hypertrophy", 
          "paroxysmal supraventricular tachycardia", 
          "acute myocardial infarction", 
          "improved glucose tolerance", 
          "long-term treatment", 
          "similar electrophysiological effects", 
          "Converting Enzyme Inhibitors", 
          "maximum plasma concentration", 
          "withdrawal of treatment", 
          "similar extent", 
          "similar proportions", 
          "term metabolic effects", 
          "low lipid solubility", 
          "infarct recurrence", 
          "bronchodilatation effect", 
          "moderate hypertension", 
          "doxazosin 1", 
          "vascular mortality", 
          "continued therapy", 
          "maintenance therapy", 
          "renal dysfunction", 
          "anginal attacks", 
          "silent ischaemia", 
          "artery surgery", 
          "gastrointestinal symptoms", 
          "tolerability profile", 
          "chest pain", 
          "renal impairment", 
          "most patients", 
          "antihypertensive effect", 
          "lipoprotein cholesterol", 
          "asthmatic patients", 
          "adult patients", 
          "renal function", 
          "maintenance dose", 
          "ventricular hypertrophy", 
          "artery disease", 
          "antianginal agent", 
          "clinical course", 
          "heart failure", 
          "cardiac reserve", 
          "term follow", 
          "extended therapy", 
          "ventricular arrhythmias", 
          "Raynaud's phenomenon", 
          "dosage adjustment", 
          "first therapy", 
          "term therapy", 
          "pregnant women", 
          "exercise duration", 
          "atrial fibrillation", 
          "maintenance treatment", 
          "treatment options", 
          "insulin resistance", 
          "multiple doses", 
          "breast milk", 
          "cardiac arrest", 
          "combination therapy", 
          "plasma levels", 
          "total clearance", 
          "filtration rate", 
          "sleep disturbances", 
          "antiarrhythmic agents", 
          "electrophysiological effects", 
          "short elimination", 
          "cardiovascular disease", 
          "comparative trials", 
          "drug classes", 
          "hypertension", 
          "lower incidence", 
          "term treatment", 
          "normal limits", 
          "early initiation", 
          "ophthalmological changes", 
          "metabolic effects", 
          "pectoris", 
          "respiratory function", 
          "final infusion", 
          "heart rate", 
          "sexual disturbances", 
          "infarction", 
          "patients", 
          "clinical relevance", 
          "cardiac arrhythmias", 
          "enzyme inhibitors", 
          "arrhythmias", 
          "early intervention", 
          "therapy", 
          "\u03b1-methyldopa", 
          "antagonist", 
          "therapeutic use", 
          "biochemical indices", 
          "maximum dosage", 
          "mortality", 
          "pharmacokinetic properties", 
          "tachycardia", 
          "triglycerides", 
          "cardiovascular medicine", 
          "dose", 
          "administration", 
          "atenolol", 
          "lipid solubility", 
          "propranolol", 
          "infusion", 
          "doses", 
          "adverse effects", 
          "daily", 
          "incidence", 
          "elimination rate", 
          "baseline phase", 
          "pattern of effects", 
          "placebo", 
          "women", 
          "treatment", 
          "greater reduction", 
          "ischaemia", 
          "bradycardia", 
          "pregnancy", 
          "duration of activity", 
          "recurrence", 
          "interindividual differences", 
          "oxygen consumption", 
          "two-thirds", 
          "disease", 
          "dialysis", 
          "inhibitors", 
          "trials", 
          "weeks", 
          "hours", 
          "drugs", 
          "additional benefit", 
          "significant changes", 
          "system effects", 
          "dosage", 
          "minutes", 
          "children", 
          "most studies", 
          "subjective indices", 
          "agents", 
          "duration", 
          "long term", 
          "lesser extent", 
          "reinfarction", 
          "hypotension", 
          "optimal response", 
          "monotherapy", 
          "ketanserin", 
          "pain", 
          "asthma", 
          "headache", 
          "doxazosin", 
          "surgery", 
          "comparative study", 
          "dysfunction", 
          "fibrillation", 
          "index", 
          "hypertrophy", 
          "infants", 
          "verapamil", 
          "salbutamol", 
          "follow", 
          "symptoms", 
          "stroke", 
          "placenta", 
          "proportion", 
          "study", 
          "cholesterol", 
          "impairment", 
          "severity", 
          "months", 
          "clearance", 
          "full effect", 
          "care", 
          "urine", 
          "response", 
          "evidence", 
          "depression", 
          "adjustment", 
          "intervention", 
          "effect", 
          "rate", 
          "increase", 
          "withdrawal", 
          "arrest", 
          "injection", 
          "control", 
          "reduction", 
          "pressure", 
          "exercise", 
          "onset", 
          "elimination", 
          "benefits", 
          "changes", 
          "occurrence", 
          "days", 
          "pressure increase", 
          "medicine", 
          "tolerance", 
          "grade", 
          "disturbances", 
          "failure", 
          "caution", 
          "options", 
          "extent", 
          "milk", 
          "majority", 
          "initiation", 
          "concentration", 
          "years", 
          "course", 
          "interval", 
          "function", 
          "preliminary investigation", 
          "levels", 
          "data", 
          "differences", 
          "decrease", 
          "activity", 
          "weakness", 
          "consumption", 
          "accumulation", 
          "relevance", 
          "penetration results", 
          "resistance", 
          "body", 
          "profile", 
          "major adjustments", 
          "use", 
          "combination", 
          "frequency", 
          "patterns", 
          "addition", 
          "time", 
          "potential", 
          "investigation", 
          "reserves", 
          "area", 
          "results", 
          "journals", 
          "trends", 
          "attacks", 
          "phenomenon", 
          "products", 
          "peak", 
          "phase", 
          "terms", 
          "class", 
          "scope", 
          "solubility", 
          "limit", 
          "properties"
        ], 
        "name": "Atenolol", 
        "pagination": "468-510", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1021698570"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003495-199142030-00007"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "1720383"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003495-199142030-00007", 
          "https://app.dimensions.ai/details/publication/pub.1021698570"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:46", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_232.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003495-199142030-00007"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-199142030-00007'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-199142030-00007'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-199142030-00007'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-199142030-00007'


     

    This table displays all metadata directly associated to this object as RDF triples.

    642 TRIPLES      21 PREDICATES      407 URIs      343 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003495-199142030-00007 schema:about N153c32e3ed434218bca59286a048baac
    2 N5d6c7026d52e4544a8ddadf052a66399
    3 N808b991dda6046ff9a7a612151fa8f9c
    4 N83b8d83b0c7a40a8a76ad05febca1bb9
    5 Nd2ee98bd42124f89b5df5d59a007400d
    6 Ndf02165b35904f1c81f9e374a96e0aa1
    7 anzsrc-for:11
    8 anzsrc-for:1102
    9 anzsrc-for:1116
    10 schema:author N3c6f9d48489c400bb5c858bed83971a2
    11 schema:citation sg:pub.10.1007/bf00051147
    12 sg:pub.10.1007/bf00114235
    13 sg:pub.10.1007/bf00265862
    14 sg:pub.10.1007/bf00265982
    15 sg:pub.10.1007/bf00314809
    16 sg:pub.10.1007/bf00315224
    17 sg:pub.10.1007/bf00542322
    18 sg:pub.10.1007/bf00543336
    19 sg:pub.10.1007/bf00543717
    20 sg:pub.10.1007/bf00543719
    21 sg:pub.10.1007/bf00543720
    22 sg:pub.10.1007/bf00543966
    23 sg:pub.10.1007/bf00544082
    24 sg:pub.10.1007/bf00546701
    25 sg:pub.10.1007/bf00556887
    26 sg:pub.10.1007/bf00558246
    27 sg:pub.10.1007/bf00561365
    28 sg:pub.10.1007/bf00609677
    29 sg:pub.10.1007/bf00679788
    30 sg:pub.10.1007/bf01856511
    31 sg:pub.10.1007/bf01857761
    32 sg:pub.10.1007/bf02395202
    33 sg:pub.10.1007/bf03348625
    34 sg:pub.10.1038/clpt.1983.34
    35 sg:pub.10.1038/clpt.1985.223
    36 sg:pub.10.1038/clpt.1987.20
    37 sg:pub.10.1038/clpt.1988.54
    38 sg:pub.10.1038/clpt.1989.198
    39 sg:pub.10.2165/00003495-197917060-00001
    40 sg:pub.10.2165/00003495-198300252-00009
    41 sg:pub.10.2165/00003495-198300252-00013
    42 sg:pub.10.2165/00003495-198300252-00015
    43 sg:pub.10.2165/00003495-198300252-00017
    44 sg:pub.10.2165/00003495-198300252-00018
    45 sg:pub.10.2165/00003495-198300252-00021
    46 sg:pub.10.2165/00003495-198300252-00026
    47 sg:pub.10.2165/00003495-198300252-00035
    48 sg:pub.10.2165/00003495-198300252-00040
    49 sg:pub.10.2165/00003495-198300252-00042
    50 sg:pub.10.2165/00003495-198300252-00044
    51 sg:pub.10.2165/00003495-198300252-00050
    52 sg:pub.10.2165/00003495-198300252-00051
    53 sg:pub.10.2165/00003495-198300252-00053
    54 sg:pub.10.2165/00003495-198300252-00055
    55 sg:pub.10.2165/00003495-198300252-00058
    56 sg:pub.10.2165/00003495-198300252-00060
    57 sg:pub.10.2165/00003495-198300252-00061
    58 sg:pub.10.2165/00003495-198300252-00062
    59 sg:pub.10.2165/00003495-198300252-00063
    60 sg:pub.10.2165/00003495-198300252-00064
    61 sg:pub.10.2165/00003495-198300252-00067
    62 sg:pub.10.2165/00003495-198300252-00074
    63 sg:pub.10.2165/00003495-198300252-00075
    64 sg:pub.10.2165/00003495-198800354-00011
    65 sg:pub.10.2165/00003495-198800362-00009
    66 schema:datePublished 1991-09
    67 schema:datePublishedReg 1991-09-01
    68 schema:description SynopsisAtenolol is a selective β1-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic use of the drug has been expanded and become better defined since it was first reviewed in the Journal in 1979.Atenolol is effective and generally well tolerated in patients with all grades of hypertension. Data from comparative studies show that when administered orally, atenolol reduces blood pressure to a similar extent, and in a similar proportion of patients, as usual therapeutic doses of other β- adrenoceptor antagonists (such as acebutolol, celiprolol, betaxolol, indenolol, metoprolol, nadolol, pindolol, propranolol, tertatolol), angiotensin converting enzyme (ACE) inhibitors (e.g. captopril, enalapril and lisinopril), calcium antagonists (e.g. amlodipine, diltiazem, felodipine, isradipine, nitrendipine, nifedipine, verapamil), doxazosin, ketanserin and α-methyldopa. Atenolol effectively lowers blood pressure in elderly patients with hypertension and in women with hypertension associated with pregnancy, and improves objective and subjective indices in patients with stable angina pectoris. Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. Early intervention with intravenous atenolol followed by oral maintenance therapy reduces infarct recurrence and cardiovascular mortality in patients with known or suspected myocardial infarction. There is also encouraging evidence of reduced mortality from cardiovascular disease during long term therapy with atenolol in patients with hypertension.Atenolol is well tolerated in most patients. Increases in plasma levels of both total triglycerides and very low density lipoprotein (VLDL) triglycerides have accompanied atenolol therapy although the clinical relevance, if any, of longer term metabolic effects has yet to be determined. Its low lipid solubility and limited brain penetration results in a lower incidence of central nervous system effects than that associated with propranolol.After many years of clinical usage atenolol is a well established treatment option in several areas of cardiovascular medicine such as mild to moderate hypertension and stable angina pectoris. Furthermore, it has also shown potential in the treatment of some cardiac arrhythmias and has been associated with reduced cardiovascular mortality in patients with hypertension and in patients with myocardial infarction.Pharmacodynamic PropertiesAtenolol is a selective and long acting β1-adrenoceptor antagonist. In patients with hypertension, oral administration of atenolol significantly reduces resting systolic and diastolic blood pressures and attenuates the blood pressure increase induced by exercise. In some studies, long term administration of atenolol 50 to 100mg daily improved left ventricular hypertrophy when present before treatment. In patients with coronary artery disease the antihypertensive effects of atenolol are accompanied by reductions in heart rate (8 to 34%) and rate-pressure product (9 to 40%). Atenolol improves indices of oxygen consumption in patients with acute myocardial infarction. Short or long term administration of atenolol 50 to 100mg daily reduces blood pressure in pregnant women.Although impaired glucose tolerance and increased insulin resistance have been reported in some patients treated with atenolol, improved glucose tolerance has been reported in others. Increases in plasma total triglycerides and very low density lipoprotein triglycerides, and decreases in high density lipoprotein cholesterol generally occur after several months’ treatment with atenolol, but these changes are less pronounced than those associated with propranolol and a trend towards a reduction in effect has been noted during long term administration.Atenolol 50 to 125mg impairs respiratory function in asthmatic patients, following single or multiple doses, to a lesser extent than propranolol, and does not significantly decrease the bronchodilatation effect of inhaled salbutamol during short or long term treatment.Pharmacokinetic PropertiesFollowing oral administration, about 50 to 60% of an atenolol dose is absorbed with maximum plasma concentrations reached within 2 to 4 hours. Atenolol is widely distributed in the body (although only a small proportion of an administered dose reaches the brain), and readily crosses the placenta. In adult patients with normal renal function the elimination half-life is about 5 to 7 hours and total clearance is about 6 L/h (100 ml/min) per 1.73m2. A shorter elimination half-life (4.5 hours) has been observed in children. However, there are wide intra- and interindividual differences in the pharmacokinetic properties of atenolol. Most absorbed atenolol is excreted unchanged in the urine. Accumulation into breast milk has been reported but plasma concentrations are negligible in infants. In patients with renal dysfunction the elimination rate is decreased and is related to glomerular filtration rate.Therapeutic EfficacyDuring long term follow-up trials with atenolol, generally 50 to 100mg once daily alone or in combination with a diuretic, goal blood pressures are achieved in about two-thirds of all patients with mild to moderate hypertension. The greatest reductions in blood pressure occur in the first 2 weeks of treatment, and blood pressure remains within normal limits during extended therapy without major adjustment of dosage.Atenolol 50 to lOOmg daily is clearly more effective than placebo in reducing blood pressure, and in comparative trials it reduced blood pressure in a similar proportion of patients, and to a similar extent, as usual therapeutic doses of other β-adrenoceptor antagonists (acebutolol, celiprolol, betaxolol, indenolol, SR metoprolol, nadolol, SR pindolol, SR propranolol, tertatolol), ACE inhibitors [captopril (100mg), enalapril (20 to 40mg) and lisinopril (20 to 80mg)], calcium antagonists [amlodipine (2.5 to 10mg), diltiazem (240 to 360mg), felodipine (10 to 20mg), isradipine (5 to 20mg), SR nifedipine (20 to 40mg), SR verapamil (240mg) and nitrendipine (20 to 40mg)], doxazosin 1 to 16mg, ketanserin 40 to 80mg and α-methyldopa 1500mg daily. Elderly patients and women with hypertension associated with pregnancy respond well to treatment with atenolol 50 and 50 to 200mg daily, respectively.In patients with stable angina pectoris, oral atenolol 100mg daily was superior to placebo and at least as effective as usual therapeutic doses of other antianginal agents in reducing the severity and frequency of anginal attacks, reducing glyceryl trinitrate consumption, improving exercise duration, and extending time to lmm ST-segment depression. Atenolol appears to eliminate the morning ischaemic episode peak in patients with silent ischaemia.In patients with hypertension, with or without evidence of ischaemia, long term atenolol therapy reduced the mortality from myocardial infarction or stroke. In addition, early initiation of atenolol therapy reduced the incidence of both vascular mortality and the occurrence of non-fatal cardiac arrests and reinfarction in patients with suspected myocardial infarction.Preliminary investigation in patients with paroxysmal supraventricular tachycardia revealed that atenolol reduced the occurrence of supraventricular tachycardia in up to 70% of patients. This benefit was maintained during long term follow-up and atenolol improved the clinical course of patients with sustained paroxysmal reciprocating supraventricular tachycardia. Following coronary artery surgery, orally administered atenolol was significantly superior to placebo in reducing the incidence of supraventricular arrhythmias and atrial fibrillation. Control of ventricular arrhythmias has also been achieved using oral atenolol therapy.TolerabilityThe most frequently reported adverse effects experienced during oral atenolol therapy for hypertension, angina pectoris and arrhythmias are bradycardia (0.6 to 10%), cold extremities/ Raynaud’s phenomenon (2 to 35%), gastrointestinal symptoms (0.5 to 32%), fatigue/weakness (1 to 51%), nightmares/sleep disturbances (6 to 26%), headache (1 to 18%), and sexual disturbances (1 to 14%). In general these effects were mild, occurred more frequently during baseline phases, usually become less frequent with continued therapy and, in most studies, necessitated withdrawal of treatment from only 3 to 6% of patients. Data from comparative studies suggest that the tolerability profile of atenolol is similar to that of other antihypertensive agents although the pattern of effects differed between drug classes. Both hypotension and bradycardia have been observed after intravenous administration of atenolol in patients with myocardial infarction. Atenolol therapy has not been associated with ophthalmological changes or clinically significant changes in haematological or biochemical indices.Dosage and AdministrationMost patients with hypertension respond to once daily oral administration of atenolol 50 to 100mg. The full effect is usually established within 2 weeks. If an optimal response is not achieved an additional antihypertensive agent such as a diuretic, calcium antagonist or ACE inhibitor could be added. It is unlikely that increasing the atenolol dose above 100 mg/day will result in additional benefit for patients receiving monotherapy or combination therapy. The majority of patients with angina pectoris will respond to 100mg daily given orally. For patients with arrhythmias a suitable initial dose is 2.5 to 5mg injected intravenously (1mg/min). This may be repeated at 5-minute intervals until a response is observed, up to a maximum dosage of 10mg. If atenolol is administered by infusion the initial dose should be 0.15 mg/kg over 20 minutes. If required, the injection or infusion may be repeated every 12 hours. Once arrhythmias have been controlled a suitable maintenance dose is 50 to 100mg once daily.For patients with suspected myocardial infarction, presenting within 12 hours of the onset of chest pain, intravenous atenolol (5mg infused over 5 minutes) should be administered immediately. A second 5mg dose may be given 10 minutes later. 15 minutes after the final infusion an oral 50mg dose should be administered. A second oral 50mg dose should be given after 12 hours and after a further 12 hours maintenance treatment with 100mg once daily should be initiated.Dosage adjustment is required in patients with severe renal impairment (creatinine clearance < 35 ml/min/ 1.73m2). Patients undergoing dialysis should be given an oral 50mg dose after each dialysis. Atenolol is not recommended for children, patients with overt heart failure or as first therapy in patients with asthma. Atenolol should be administered with caution in patients receiving concomitant class I antiarrhythmic agents or verapamil as these drugs have similar electrophysiological effects. Care must also be taken when administering atenolol to patients whose cardiac reserve is poor.
    69 schema:genre article
    70 schema:isAccessibleForFree false
    71 schema:isPartOf N3bbb3726ee4149f0a7a7d6c511c3b187
    72 N80a5ed71e6d94ed1810e091438901c97
    73 sg:journal.1084788
    74 schema:keywords ACE inhibitors
    75 Converting Enzyme Inhibitors
    76 Pharmacokinetic PropertiesFollowing oral administration
    77 Raynaud's phenomenon
    78 ST-segment depression
    79 accumulation
    80 activity
    81 acute myocardial infarction
    82 addition
    83 additional antihypertensive agents
    84 additional benefit
    85 adjustment
    86 administration
    87 adult patients
    88 adverse effects
    89 agents
    90 angina pectoris
    91 anginal attacks
    92 angiotensin converting enzyme (ACE) inhibitors
    93 antagonist
    94 antianginal agent
    95 antiarrhythmic agents
    96 antihypertensive agents
    97 antihypertensive effect
    98 area
    99 arrest
    100 arrhythmias
    101 artery disease
    102 artery surgery
    103 asthma
    104 asthmatic patients
    105 atenolol
    106 atenolol 50
    107 atenolol therapy
    108 atrial fibrillation
    109 attacks
    110 baseline phase
    111 benefits
    112 biochemical indices
    113 blood pressure
    114 blood pressure increase
    115 body
    116 bradycardia
    117 breast milk
    118 bronchodilatation effect
    119 calcium antagonists
    120 cardiac arrest
    121 cardiac arrhythmias
    122 cardiac reserve
    123 cardiovascular disease
    124 cardiovascular medicine
    125 cardiovascular mortality
    126 care
    127 caution
    128 central nervous system effects
    129 changes
    130 chest pain
    131 children
    132 cholesterol
    133 class
    134 class I antiarrhythmic agents
    135 clearance
    136 clinical course
    137 clinical relevance
    138 combination
    139 combination therapy
    140 comparative study
    141 comparative trials
    142 concentration
    143 consumption
    144 continued therapy
    145 control
    146 coronary artery disease
    147 coronary artery surgery
    148 course
    149 daily
    150 daily oral administration
    151 data
    152 days
    153 decrease
    154 density lipoprotein cholesterol
    155 density lipoprotein triglycerides
    156 depression
    157 dialysis
    158 diastolic blood pressure
    159 differences
    160 disease
    161 disturbances
    162 dosage
    163 dosage adjustment
    164 dose
    165 doses
    166 doxazosin
    167 doxazosin 1
    168 drug classes
    169 drugs
    170 duration
    171 duration of activity
    172 dysfunction
    173 early initiation
    174 early intervention
    175 effect
    176 elderly patients
    177 electrophysiological effects
    178 elimination
    179 elimination rate
    180 enzyme inhibitors
    181 evidence
    182 evidence of ischaemia
    183 exercise
    184 exercise duration
    185 extended therapy
    186 extent
    187 failure
    188 fatigue/weakness
    189 fibrillation
    190 filtration rate
    191 final infusion
    192 first therapy
    193 follow
    194 frequency
    195 full effect
    196 function
    197 gastrointestinal symptoms
    198 glomerular filtration rate
    199 glucose tolerance
    200 glyceryl trinitrate consumption
    201 goal blood pressure
    202 grade
    203 grades of hypertension
    204 greater reduction
    205 headache
    206 heart failure
    207 heart rate
    208 high-density lipoprotein cholesterol
    209 hours
    210 hypertension
    211 hypertrophy
    212 hypotension
    213 impair respiratory function
    214 impaired glucose tolerance
    215 impairment
    216 improved glucose tolerance
    217 incidence
    218 increase
    219 index
    220 infants
    221 infarct recurrence
    222 infarction
    223 infusion
    224 inhibitors
    225 initial dose
    226 initiation
    227 injection
    228 insulin resistance
    229 interindividual differences
    230 interval
    231 intervention
    232 intravenous administration
    233 intravenous atenolol
    234 investigation
    235 ischaemia
    236 journals
    237 ketanserin
    238 left ventricular hypertrophy
    239 lesser extent
    240 levels
    241 limit
    242 lipid solubility
    243 lipoprotein cholesterol
    244 lipoprotein triglycerides
    245 long term
    246 long-term administration
    247 long-term follow
    248 long-term metabolic effects
    249 long-term therapy
    250 long-term treatment
    251 low density lipoprotein triglycerides
    252 low lipid solubility
    253 lower incidence
    254 maintenance dose
    255 maintenance therapy
    256 maintenance treatment
    257 major adjustments
    258 majority
    259 majority of patients
    260 maximum dosage
    261 maximum plasma concentration
    262 medicine
    263 metabolic effects
    264 milk
    265 minutes
    266 moderate hypertension
    267 monotherapy
    268 months
    269 mortality
    270 most patients
    271 most studies
    272 multiple doses
    273 myocardial infarction
    274 nervous system effects
    275 non-fatal cardiac arrest
    276 normal limits
    277 normal renal function
    278 occurrence
    279 onset
    280 ophthalmological changes
    281 optimal response
    282 options
    283 oral administration
    284 oral atenolol
    285 oral atenolol therapy
    286 oral maintenance therapy
    287 overt heart failure
    288 oxygen consumption
    289 pain
    290 paroxysmal supraventricular tachycardia
    291 patients
    292 pattern of effects
    293 patterns
    294 peak
    295 pectoris
    296 penetration results
    297 pharmacokinetic properties
    298 phase
    299 phenomenon
    300 placebo
    301 placenta
    302 plasma concentrations
    303 plasma levels
    304 plasma total triglycerides
    305 potential
    306 pregnancy
    307 pregnant women
    308 preliminary investigation
    309 pressure
    310 pressure increase
    311 products
    312 profile
    313 properties
    314 proportion
    315 propranolol
    316 rate
    317 rate-pressure product
    318 recurrence
    319 reduced cardiovascular mortality
    320 reduction
    321 reinfarction
    322 relevance
    323 renal dysfunction
    324 renal function
    325 renal impairment
    326 reserves
    327 resistance
    328 respiratory function
    329 response
    330 results
    331 salbutamol
    332 scope
    333 selective β1-adrenoceptor antagonist
    334 severe renal impairment
    335 severity
    336 sexual disturbances
    337 short elimination
    338 significant changes
    339 silent ischaemia
    340 similar electrophysiological effects
    341 similar extent
    342 similar proportions
    343 sleep disturbances
    344 solubility
    345 stable angina pectoris
    346 stroke
    347 study
    348 subjective indices
    349 suitable initial dose
    350 supraventricular arrhythmias
    351 supraventricular tachycardia
    352 surgery
    353 symptoms
    354 system effects
    355 tachycardia
    356 term administration
    357 term follow
    358 term metabolic effects
    359 term therapy
    360 term treatment
    361 terms
    362 therapeutic doses
    363 therapeutic use
    364 therapy
    365 time
    366 tolerability profile
    367 tolerance
    368 total clearance
    369 total triglycerides
    370 treatment
    371 treatment options
    372 trends
    373 trials
    374 triglycerides
    375 two-thirds
    376 urine
    377 use
    378 usual therapeutic doses
    379 vascular mortality
    380 ventricular arrhythmias
    381 ventricular hypertrophy
    382 verapamil
    383 weakness
    384 weeks
    385 weeks of treatment
    386 withdrawal
    387 withdrawal of treatment
    388 women
    389 years
    390 α-methyldopa
    391 β-adrenoceptor antagonists
    392 β1-adrenoceptor antagonist
    393 schema:name Atenolol
    394 schema:pagination 468-510
    395 schema:productId N09beb92d635e4a6c92dfcc228373b1b8
    396 N1d9cc663404245c8873831b7863fa865
    397 Nad8e4111f0a54064a358077c36168f4c
    398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021698570
    399 https://doi.org/10.2165/00003495-199142030-00007
    400 schema:sdDatePublished 2022-09-02T15:46
    401 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    402 schema:sdPublisher N043fd8b1c044451e957b31de7a7ef29d
    403 schema:url https://doi.org/10.2165/00003495-199142030-00007
    404 sgo:license sg:explorer/license/
    405 sgo:sdDataset articles
    406 rdf:type schema:ScholarlyArticle
    407 N043fd8b1c044451e957b31de7a7ef29d schema:name Springer Nature - SN SciGraph project
    408 rdf:type schema:Organization
    409 N09beb92d635e4a6c92dfcc228373b1b8 schema:name doi
    410 schema:value 10.2165/00003495-199142030-00007
    411 rdf:type schema:PropertyValue
    412 N153c32e3ed434218bca59286a048baac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    413 schema:name Drug Evaluation
    414 rdf:type schema:DefinedTerm
    415 N1d9cc663404245c8873831b7863fa865 schema:name dimensions_id
    416 schema:value pub.1021698570
    417 rdf:type schema:PropertyValue
    418 N3bbb3726ee4149f0a7a7d6c511c3b187 schema:issueNumber 3
    419 rdf:type schema:PublicationIssue
    420 N3c6f9d48489c400bb5c858bed83971a2 rdf:first sg:person.01065012230.06
    421 rdf:rest Nfa2634d12f5d410dbf8cab0c8b9b1be7
    422 N5d6c7026d52e4544a8ddadf052a66399 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    423 schema:name Coronary Disease
    424 rdf:type schema:DefinedTerm
    425 N808b991dda6046ff9a7a612151fa8f9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    426 schema:name Humans
    427 rdf:type schema:DefinedTerm
    428 N80a5ed71e6d94ed1810e091438901c97 schema:volumeNumber 42
    429 rdf:type schema:PublicationVolume
    430 N83b8d83b0c7a40a8a76ad05febca1bb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    431 schema:name Hypertension
    432 rdf:type schema:DefinedTerm
    433 N8cd190c089db4a7e84aa90ff0e6f1a21 rdf:first sg:person.01232517615.24
    434 rdf:rest rdf:nil
    435 Nad8e4111f0a54064a358077c36168f4c schema:name pubmed_id
    436 schema:value 1720383
    437 rdf:type schema:PropertyValue
    438 Nd2ee98bd42124f89b5df5d59a007400d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    439 schema:name Atenolol
    440 rdf:type schema:DefinedTerm
    441 Ndf02165b35904f1c81f9e374a96e0aa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    442 schema:name Arrhythmias, Cardiac
    443 rdf:type schema:DefinedTerm
    444 Nfa2634d12f5d410dbf8cab0c8b9b1be7 rdf:first sg:person.01026511116.28
    445 rdf:rest N8cd190c089db4a7e84aa90ff0e6f1a21
    446 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    447 schema:name Medical and Health Sciences
    448 rdf:type schema:DefinedTerm
    449 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    450 schema:name Cardiorespiratory Medicine and Haematology
    451 rdf:type schema:DefinedTerm
    452 anzsrc-for:1116 schema:inDefinedTermSet anzsrc-for:
    453 schema:name Medical Physiology
    454 rdf:type schema:DefinedTerm
    455 sg:journal.1084788 schema:issn 0012-6667
    456 1179-1950
    457 schema:name Drugs
    458 schema:publisher Springer Nature
    459 rdf:type schema:Periodical
    460 sg:person.01026511116.28 schema:affiliation grid-institutes:grid.420067.7
    461 schema:familyName Murdoch
    462 schema:givenName David
    463 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026511116.28
    464 rdf:type schema:Person
    465 sg:person.01065012230.06 schema:affiliation grid-institutes:grid.420067.7
    466 schema:familyName Wadworth
    467 schema:givenName Alison N.
    468 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065012230.06
    469 rdf:type schema:Person
    470 sg:person.01232517615.24 schema:affiliation grid-institutes:grid.420067.7
    471 schema:familyName Brogden
    472 schema:givenName Rex N.
    473 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232517615.24
    474 rdf:type schema:Person
    475 sg:pub.10.1007/bf00051147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008110367
    476 https://doi.org/10.1007/bf00051147
    477 rdf:type schema:CreativeWork
    478 sg:pub.10.1007/bf00114235 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052316887
    479 https://doi.org/10.1007/bf00114235
    480 rdf:type schema:CreativeWork
    481 sg:pub.10.1007/bf00265862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016200197
    482 https://doi.org/10.1007/bf00265862
    483 rdf:type schema:CreativeWork
    484 sg:pub.10.1007/bf00265982 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026394691
    485 https://doi.org/10.1007/bf00265982
    486 rdf:type schema:CreativeWork
    487 sg:pub.10.1007/bf00314809 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052228201
    488 https://doi.org/10.1007/bf00314809
    489 rdf:type schema:CreativeWork
    490 sg:pub.10.1007/bf00315224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023933809
    491 https://doi.org/10.1007/bf00315224
    492 rdf:type schema:CreativeWork
    493 sg:pub.10.1007/bf00542322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049097189
    494 https://doi.org/10.1007/bf00542322
    495 rdf:type schema:CreativeWork
    496 sg:pub.10.1007/bf00543336 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012113650
    497 https://doi.org/10.1007/bf00543336
    498 rdf:type schema:CreativeWork
    499 sg:pub.10.1007/bf00543717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003850908
    500 https://doi.org/10.1007/bf00543717
    501 rdf:type schema:CreativeWork
    502 sg:pub.10.1007/bf00543719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024722144
    503 https://doi.org/10.1007/bf00543719
    504 rdf:type schema:CreativeWork
    505 sg:pub.10.1007/bf00543720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017575493
    506 https://doi.org/10.1007/bf00543720
    507 rdf:type schema:CreativeWork
    508 sg:pub.10.1007/bf00543966 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033763100
    509 https://doi.org/10.1007/bf00543966
    510 rdf:type schema:CreativeWork
    511 sg:pub.10.1007/bf00544082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045490019
    512 https://doi.org/10.1007/bf00544082
    513 rdf:type schema:CreativeWork
    514 sg:pub.10.1007/bf00546701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026163841
    515 https://doi.org/10.1007/bf00546701
    516 rdf:type schema:CreativeWork
    517 sg:pub.10.1007/bf00556887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043627001
    518 https://doi.org/10.1007/bf00556887
    519 rdf:type schema:CreativeWork
    520 sg:pub.10.1007/bf00558246 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003035238
    521 https://doi.org/10.1007/bf00558246
    522 rdf:type schema:CreativeWork
    523 sg:pub.10.1007/bf00561365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030807023
    524 https://doi.org/10.1007/bf00561365
    525 rdf:type schema:CreativeWork
    526 sg:pub.10.1007/bf00609677 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022238970
    527 https://doi.org/10.1007/bf00609677
    528 rdf:type schema:CreativeWork
    529 sg:pub.10.1007/bf00679788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012896847
    530 https://doi.org/10.1007/bf00679788
    531 rdf:type schema:CreativeWork
    532 sg:pub.10.1007/bf01856511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011645853
    533 https://doi.org/10.1007/bf01856511
    534 rdf:type schema:CreativeWork
    535 sg:pub.10.1007/bf01857761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005603429
    536 https://doi.org/10.1007/bf01857761
    537 rdf:type schema:CreativeWork
    538 sg:pub.10.1007/bf02395202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040426368
    539 https://doi.org/10.1007/bf02395202
    540 rdf:type schema:CreativeWork
    541 sg:pub.10.1007/bf03348625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041545801
    542 https://doi.org/10.1007/bf03348625
    543 rdf:type schema:CreativeWork
    544 sg:pub.10.1038/clpt.1983.34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035061855
    545 https://doi.org/10.1038/clpt.1983.34
    546 rdf:type schema:CreativeWork
    547 sg:pub.10.1038/clpt.1985.223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036603739
    548 https://doi.org/10.1038/clpt.1985.223
    549 rdf:type schema:CreativeWork
    550 sg:pub.10.1038/clpt.1987.20 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038511633
    551 https://doi.org/10.1038/clpt.1987.20
    552 rdf:type schema:CreativeWork
    553 sg:pub.10.1038/clpt.1988.54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027933705
    554 https://doi.org/10.1038/clpt.1988.54
    555 rdf:type schema:CreativeWork
    556 sg:pub.10.1038/clpt.1989.198 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038050110
    557 https://doi.org/10.1038/clpt.1989.198
    558 rdf:type schema:CreativeWork
    559 sg:pub.10.2165/00003495-197917060-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007024415
    560 https://doi.org/10.2165/00003495-197917060-00001
    561 rdf:type schema:CreativeWork
    562 sg:pub.10.2165/00003495-198300252-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039300203
    563 https://doi.org/10.2165/00003495-198300252-00009
    564 rdf:type schema:CreativeWork
    565 sg:pub.10.2165/00003495-198300252-00013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023531610
    566 https://doi.org/10.2165/00003495-198300252-00013
    567 rdf:type schema:CreativeWork
    568 sg:pub.10.2165/00003495-198300252-00015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050590745
    569 https://doi.org/10.2165/00003495-198300252-00015
    570 rdf:type schema:CreativeWork
    571 sg:pub.10.2165/00003495-198300252-00017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031521587
    572 https://doi.org/10.2165/00003495-198300252-00017
    573 rdf:type schema:CreativeWork
    574 sg:pub.10.2165/00003495-198300252-00018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047102313
    575 https://doi.org/10.2165/00003495-198300252-00018
    576 rdf:type schema:CreativeWork
    577 sg:pub.10.2165/00003495-198300252-00021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024610242
    578 https://doi.org/10.2165/00003495-198300252-00021
    579 rdf:type schema:CreativeWork
    580 sg:pub.10.2165/00003495-198300252-00026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014777390
    581 https://doi.org/10.2165/00003495-198300252-00026
    582 rdf:type schema:CreativeWork
    583 sg:pub.10.2165/00003495-198300252-00035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049915737
    584 https://doi.org/10.2165/00003495-198300252-00035
    585 rdf:type schema:CreativeWork
    586 sg:pub.10.2165/00003495-198300252-00040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024510787
    587 https://doi.org/10.2165/00003495-198300252-00040
    588 rdf:type schema:CreativeWork
    589 sg:pub.10.2165/00003495-198300252-00042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023486384
    590 https://doi.org/10.2165/00003495-198300252-00042
    591 rdf:type schema:CreativeWork
    592 sg:pub.10.2165/00003495-198300252-00044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006145850
    593 https://doi.org/10.2165/00003495-198300252-00044
    594 rdf:type schema:CreativeWork
    595 sg:pub.10.2165/00003495-198300252-00050 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028087420
    596 https://doi.org/10.2165/00003495-198300252-00050
    597 rdf:type schema:CreativeWork
    598 sg:pub.10.2165/00003495-198300252-00051 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036487532
    599 https://doi.org/10.2165/00003495-198300252-00051
    600 rdf:type schema:CreativeWork
    601 sg:pub.10.2165/00003495-198300252-00053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004932076
    602 https://doi.org/10.2165/00003495-198300252-00053
    603 rdf:type schema:CreativeWork
    604 sg:pub.10.2165/00003495-198300252-00055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009622562
    605 https://doi.org/10.2165/00003495-198300252-00055
    606 rdf:type schema:CreativeWork
    607 sg:pub.10.2165/00003495-198300252-00058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048647516
    608 https://doi.org/10.2165/00003495-198300252-00058
    609 rdf:type schema:CreativeWork
    610 sg:pub.10.2165/00003495-198300252-00060 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041628380
    611 https://doi.org/10.2165/00003495-198300252-00060
    612 rdf:type schema:CreativeWork
    613 sg:pub.10.2165/00003495-198300252-00061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042067518
    614 https://doi.org/10.2165/00003495-198300252-00061
    615 rdf:type schema:CreativeWork
    616 sg:pub.10.2165/00003495-198300252-00062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046387025
    617 https://doi.org/10.2165/00003495-198300252-00062
    618 rdf:type schema:CreativeWork
    619 sg:pub.10.2165/00003495-198300252-00063 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028142717
    620 https://doi.org/10.2165/00003495-198300252-00063
    621 rdf:type schema:CreativeWork
    622 sg:pub.10.2165/00003495-198300252-00064 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041104400
    623 https://doi.org/10.2165/00003495-198300252-00064
    624 rdf:type schema:CreativeWork
    625 sg:pub.10.2165/00003495-198300252-00067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007269274
    626 https://doi.org/10.2165/00003495-198300252-00067
    627 rdf:type schema:CreativeWork
    628 sg:pub.10.2165/00003495-198300252-00074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035816881
    629 https://doi.org/10.2165/00003495-198300252-00074
    630 rdf:type schema:CreativeWork
    631 sg:pub.10.2165/00003495-198300252-00075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027864937
    632 https://doi.org/10.2165/00003495-198300252-00075
    633 rdf:type schema:CreativeWork
    634 sg:pub.10.2165/00003495-198800354-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006554903
    635 https://doi.org/10.2165/00003495-198800354-00011
    636 rdf:type schema:CreativeWork
    637 sg:pub.10.2165/00003495-198800362-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005571736
    638 https://doi.org/10.2165/00003495-198800362-00009
    639 rdf:type schema:CreativeWork
    640 grid-institutes:grid.420067.7 schema:alternateName Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand
    641 schema:name Adis International Limited, 41 Centorian Drive, Private Bag, Mairangi Bay, Auckland 10, New Zealand
    642 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...